Premium
Identification of key amino acids responsible for the distinct aggregation properties of microtubule‐associated protein 2 and tau
Author(s) -
Xie Ce,
Soeda Yoshiyuki,
Shinzaki Yuki,
In Yasuko,
Tomoo Koji,
Ihara Yasuo,
Miyasaka Tomohiro
Publication year - 2015
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/jnc.13228
Subject(s) - tau protein , microtubule , microtubule associated protein , chemistry , microbiology and biotechnology , biology , alzheimer's disease , medicine , disease , pathology
The carboxyl‐terminal sequence of tau composes the framework for its intracellular inclusions that appear in diverse neurodegenerative disorders known as tauopathies. However, microtubule‐associated protein 2 ( MAP 2), which contains a homologous carboxyl‐terminal sequence of tau, is undetectable in the mature tau inclusions. The mechanisms underlying this phenomenon have remained largely unknown. Here, we show that tau and MAP 2 have different aggregation properties: tau aggregates to form filaments but MAP 2 remains to be granules. Exchanging 221 YKPV 224 of tau (0N3R) near the PHF 6 motif for 340 TKKI 343 of MAP 2c profoundly changed aggregation properties, suggesting that the YKPV motif is important for filament formation, whereas the TKKI motif is for granule formation. Thus, these minimal sequences may determine the different fates of tau and MAP 2 in the formation of inclusions in tauopathies.Tau and microtubule‐associated protein 2 (MAP2) are homologous microtubule‐associated proteins in neurons. So far, it is largely unknown why tau but not MAP2 is selectively involved in the filamentous inclusions (neurofibrillary tangles, NFT) formation in tauopathies, including Alzheimer's disease. In this study, we found that the difference of only two amino acids in tau and MAP2 sequences may determine their different fates in tauopathies. These results may lead to the elucidation of tau deregulation in pathological conditions.